DE69736331D1 - Immunstimulierende nukleinsaeuremolekuele - Google Patents

Immunstimulierende nukleinsaeuremolekuele

Info

Publication number
DE69736331D1
DE69736331D1 DE69736331T DE69736331T DE69736331D1 DE 69736331 D1 DE69736331 D1 DE 69736331D1 DE 69736331 T DE69736331 T DE 69736331T DE 69736331 T DE69736331 T DE 69736331T DE 69736331 D1 DE69736331 D1 DE 69736331D1
Authority
DE
Germany
Prior art keywords
nucleic acid
acid molecules
immunostimulatory oligonucleotide
bases
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69736331T
Other languages
English (en)
Other versions
DE69736331T2 (de
Inventor
M Krieg
N Kline
Dennis Klinman
Alfred D Steinberg
George Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation
United States Department of Health and Human Services
Original Assignee
University of Iowa Research Foundation
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24968901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69736331(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Iowa Research Foundation, United States Department of Health and Human Services filed Critical University of Iowa Research Foundation
Publication of DE69736331D1 publication Critical patent/DE69736331D1/de
Application granted granted Critical
Publication of DE69736331T2 publication Critical patent/DE69736331T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
DE69736331T 1996-10-30 1997-10-30 Immunstimulierende nukleinsaeuremolekuele Revoked DE69736331T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/738,652 US6207646B1 (en) 1994-07-15 1996-10-30 Immunostimulatory nucleic acid molecules
US738652 1996-10-30
PCT/US1997/019791 WO1998018810A1 (en) 1996-10-30 1997-10-30 Immunostimulatory nucleic acid molecules

Publications (2)

Publication Number Publication Date
DE69736331D1 true DE69736331D1 (de) 2006-08-24
DE69736331T2 DE69736331T2 (de) 2007-08-09

Family

ID=24968901

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736331T Revoked DE69736331T2 (de) 1996-10-30 1997-10-30 Immunstimulierende nukleinsaeuremolekuele

Country Status (14)

Country Link
US (32) US6207646B1 (de)
EP (5) EP2322615A1 (de)
JP (5) JP2001503267A (de)
KR (1) KR100689942B1 (de)
CN (2) CN101265285A (de)
AT (1) ATE332966T1 (de)
AU (3) AU5242498A (de)
CA (1) CA2270345C (de)
DE (1) DE69736331T2 (de)
DK (1) DK0948510T3 (de)
ES (2) ES2268736T3 (de)
NZ (1) NZ335397A (de)
PT (1) PT948510E (de)
WO (1) WO1998018810A1 (de)

Families Citing this family (899)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6498147B2 (en) * 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
CA2110946A1 (en) * 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US20030109469A1 (en) * 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US7034007B1 (en) * 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0909323B1 (de) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bakterioferritin aus helicobacter pylori
CA2244946C (en) * 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
US20080119427A1 (en) * 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JP4391592B2 (ja) 1996-10-25 2009-12-24 スリーエム カンパニー Ｔｈ２介在性および関連疾患治療のための免疫応答修飾化合物
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ES2195317T3 (es) * 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
CA2281838A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) * 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
EP1003531B1 (de) 1997-05-20 2007-08-22 Ottawa Health Research Institute Verfahren zur Herstellung von Nukleinsäurekonstrukten
WO1998055609A1 (en) * 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
EP1374894A3 (de) * 1997-06-06 2004-09-22 Dynavax Technologies Corporation Immunstimulierende Oligonukleotide, Zusammensetzungen und Verwendungen davon
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE408422T1 (de) * 1997-07-03 2008-10-15 Donald E Macfarlane Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
AU2003203948B2 (en) * 1997-09-05 2005-12-22 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
PT1009413E (pt) * 1997-09-05 2007-05-31 Univ California Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1077708A1 (de) * 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methoden zur preventiven und therapeutischen behandlung von parasitären infektionen und damit verbundener krankheiten mittels cpg oligonukleotiden
AU760795B2 (en) * 1998-05-14 2003-05-22 Coley Pharmaceutical Gmbh Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1079824T3 (da) 1998-05-19 2011-11-21 Res Dev Foundation Triterpen-sammensætninger og fremgangsmåder til anvendelse deraf
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
KR19990086271A (ko) * 1998-05-27 1999-12-15 손경식 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
JP2002521489A (ja) * 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
ATE315405T1 (de) * 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
JP2003524602A (ja) * 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
CA2344558A1 (en) * 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
AU770464B2 (en) * 1998-12-22 2004-02-19 Seer Pharmaceuticals, Llc Treatment of skin lesions
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
DE60044236D1 (de) * 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
GB2348132B (en) * 1999-03-02 2004-08-04 Nedaa Abdul-Ghani Nasif Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
EP1176966B1 (de) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU4244400A (en) * 1999-04-15 2000-11-02 Board Of Regents, The University Of Texas System Ppgpp and pppgpp as immunomodulatory agents
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
AU762857B2 (en) * 1999-04-20 2003-07-10 Smithkline Beecham Biologicals (Sa) Vaccine
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
ES2250151T3 (es) * 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Uso de cpg como adyuvante de vacuna contra vih.
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
FR2795963A1 (fr) * 1999-07-08 2001-01-12 Pasteur Merieux Serums Vacc Polynucleotide immunostimulant
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
DE60017259T2 (de) * 1999-08-13 2005-12-08 Hybridon, Inc., Cambridge Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
US7479285B1 (en) 1999-08-19 2009-01-20 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
AU780535B2 (en) * 1999-08-27 2005-03-24 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
IL148844A0 (en) * 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1688147A1 (de) * 1999-09-27 2006-08-09 Coley Pharmaceutical Group, Inc. Verfahren mittels durch Nukleinsäuren induziertes immunstimulatorisches Interferon
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001051500A1 (en) * 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US6552006B2 (en) 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2399550A1 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20030130217A1 (en) * 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2001062092A1 (en) * 2000-02-25 2001-08-30 Thomas Jefferson University Formulations and methods for using the same to elicit an immune response
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020142978A1 (en) * 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
AU2001257366B2 (en) * 2000-05-01 2006-03-16 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US6696064B2 (en) * 2000-06-20 2004-02-24 The United States Of America As Represented By The Department Of Health And Human Services Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy
EP1315672A4 (de) 2000-06-22 2006-04-26 Rxkinetix Inc Verabreichungsträgerzusammensetzung und verfahren zur verabreichung von antigenen und anderen wirkstoffen
EP1296714B1 (de) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
WO2002002172A1 (en) * 2000-06-30 2002-01-10 Univ Jefferson Dna palindrome - oligoguanylic acid compositions and uses thereof
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
WO2002016549A2 (en) * 2000-08-25 2002-02-28 Yeda Research And Development Co. Ltd. METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
EP1366077B1 (de) 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
EP2292632A3 (de) * 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation der immunostimulatorischen Aktivität von immunostimulierenden Oligonukleotidanaloga durch positionelle chemische Veränderungen
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US20060142202A1 (en) * 2000-12-08 2006-06-29 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
EP1364010B1 (de) * 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatorische polynukleotide und verfahren zur deren verwendung
EP1358884A1 (de) * 2001-01-12 2003-11-05 Amato Pharmaceutical Products, Ltd. Präventivmittel gegen mikrobielle infektionen
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
DE10290185D2 (de) * 2001-01-31 2004-04-15 Mologen Forschungs Entwicklung Tumorvakzine
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
CN101124237A (zh) * 2001-04-13 2008-02-13 惠氏 酿脓链球菌的表面蛋白
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
US7034140B2 (en) * 2001-04-24 2006-04-25 E.I. Du Pont De Nemours And Company Genes involved in isoprenoid compound production
EP1390494A2 (de) 2001-05-21 2004-02-25 Intercell AG Verfahren zur stabilisierung von nukleinsäuren
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
KR100985457B1 (ko) 2001-06-21 2010-10-06 다이나박스 테크놀로지 코퍼레이션 키메라 면역조절 화합물 및 그것들의 사용 방법
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20030072762A1 (en) * 2001-08-03 2003-04-17 Van De Winkel Jan G. J. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies
AU2002326561B2 (en) * 2001-08-07 2008-04-03 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EA007232B1 (ru) * 2001-08-17 2006-08-25 Коли Фармасьютикал Гмбх Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
EP2518142B1 (de) 2001-08-24 2015-07-15 UVic Industry Partnerships Inc. Proaerolysin enthaltend Proteaseaktivierungssequenzen und Verfahren zur Anwendung bei der Behandlung von Prostatakrebs
CA2458876A1 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
EP1435987A4 (de) * 2001-09-07 2005-11-23 Univ Boston Verfahren und zusammensetzung zur behandlung von erkrankungen im zusammenhang mit dem immunonkomplex
EP1425040A2 (de) * 2001-09-14 2004-06-09 Cytos Biotechnology AG Steigerung der durch virusähnliche partikel hervorgerufenen immunantwort durch in-vivo aktivierung von antigen-präsentierenden zellen
EP1450856B1 (de) 2001-09-14 2009-11-11 Cytos Biotechnology AG VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
WO2004012669A2 (en) 2002-08-01 2004-02-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003031573A2 (en) * 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
KR20050048539A (ko) * 2001-10-06 2005-05-24 메리얼엘엘씨 ＣｐＧ 제제 및 관련된 방법
AU2002346960A1 (en) 2001-10-06 2003-04-22 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2002360278A1 (en) * 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003039595A2 (en) * 2001-11-07 2003-05-15 Inex Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
EP1441758A2 (de) * 2001-11-09 2004-08-04 MediGene Aktiengesellschaft Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
DK1719511T3 (da) * 2001-11-16 2009-04-14 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
JP4646516B2 (ja) * 2002-02-20 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着したポリペプチド含有分子を有する微粒子
US7030129B2 (en) * 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
EP2258712A3 (de) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
AU2003218181A1 (en) * 2002-03-15 2003-09-29 Multicell Immunotherapeutics, Inc. Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
CA2479118A1 (en) * 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
NZ535952A (en) * 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
KR100456681B1 (ko) * 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en) * 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
WO2003103586A2 (en) * 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
ATE489969T1 (de) * 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
SG167667A1 (en) * 2002-07-03 2011-01-28 Coley Pharm Group Inc Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en) * 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
US20060270620A1 (en) * 2002-07-23 2006-11-30 University Of South Florida Method of Enhancing Therapeutic Effect of Nucleic Acids
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7595303B1 (en) * 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
EA008940B1 (ru) * 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
EP1537418A2 (de) 2002-09-13 2005-06-08 Intercell AG Verfahren zur isolierung von hepatitis c virus peptiden
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
AU2003268737A1 (en) * 2002-10-02 2004-04-23 Mochida Pharmaceutical Co., Ltd. Novel method of constructing monoclonal antibody
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
EP2351579B1 (de) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Poylpeptidimpfstoffe zum breiten Schutz gegen hypervirulente Meningo-kokken-Linien
US20060148064A1 (en) * 2002-10-25 2006-07-06 Srivastava Pramod K Apparatus and method for immunotherapy of a cancer through controlled cell lysis
NZ540098A (en) * 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2003304107B2 (en) * 2002-11-01 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US8604183B2 (en) * 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
DK1569696T3 (da) * 2002-11-21 2010-11-15 Bayhill Therapeutics Inc Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2006050498A2 (en) 2004-11-02 2006-05-11 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003300831A1 (en) * 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US7625872B2 (en) * 2002-12-23 2009-12-01 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
DK1992635T3 (da) 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
EP2263687B1 (de) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogene zusammensetzungen enthaltend phospholipid
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
EP1599726A4 (de) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selektive modulation von tlr-vermittelter biologischer aktivität
WO2004078138A2 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
CN100439386C (zh) * 2003-03-05 2008-12-03 长春华普生物技术有限公司 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
KR20050109562A (ko) * 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
EP1608403A2 (de) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
AU2004229478B2 (en) * 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
EP1620547B1 (de) 2003-04-21 2014-06-18 Archemix LLC Stabilisierte aptamere für blutplättchen-wachstumsfaktor und ihre verwendung als onkologietherapeutika
US7871984B2 (en) * 2003-04-23 2011-01-18 Yukio Sato Methylated CpG polynucleotide
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
WO2004096136A2 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
WO2004100965A1 (ja) * 2003-05-15 2004-11-25 Japan Science And Technology Agency 免疫刺激剤
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
EP1633778B1 (de) 2003-06-05 2013-09-11 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Konjugate der poly-gamma-glutamsäure zur immunisierung gegen bacilli
JP4874801B2 (ja) * 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
US7410975B2 (en) * 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
AU2004255470B2 (en) * 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
CA2533128A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
JP2007501252A (ja) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
WO2005018556A2 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
US20050048072A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
RU2006105101A (ru) * 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
AU2004268665A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
WO2005023190A2 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
US8871782B2 (en) * 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
NZ546275A (en) * 2003-10-30 2009-05-31 Coley Pharm Gmbh C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
AU2004285575A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
US8598192B2 (en) * 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
AR046781A1 (es) * 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
US20050287118A1 (en) * 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) * 2003-11-26 2005-12-15 Epitomics, Inc. High-throughput method of DNA immunogen preparation and immunization
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
JP2007513165A (ja) * 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物を含む併用薬および治療方法
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
SI2336147T1 (sl) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
JP4817599B2 (ja) * 2003-12-25 2011-11-16 独立行政法人科学技術振興機構 免疫活性増強剤とこれを用いた免疫活性の増強方法
WO2005066170A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2551399A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005067500A2 (en) * 2003-12-30 2005-07-28 3M Innovative Properties Company Enhancement of immune responses
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
WO2005072290A2 (en) * 2004-01-23 2005-08-11 Joslin Diabetes Center Methods of treating, reducing, or preventing autoimmune conditions
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
EP1716234B1 (de) * 2004-02-20 2013-10-02 Mologen AG Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
EP2545931A1 (de) 2004-03-19 2013-01-16 Herbs Spring, LLC Kräutertherapie zur Behandlung von Lebensmittelallergie
AU2005228150A1 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
JP2007531746A (ja) * 2004-04-02 2007-11-08 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｉｌ−１０応答を誘導するための免疫活性化核酸
US20050260755A1 (en) * 2004-04-06 2005-11-24 Isis Pharmaceuticals, Inc. Sequential delivery of oligomeric compounds
US20050239758A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of multiple sclerosis
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
CA2564855A1 (en) * 2004-04-28 2005-10-28 3M Innovative Properties Company Compositions and methods for mucosal vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
AU2005247341B2 (en) * 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CN1296378C (zh) * 2004-05-17 2007-01-24 中国人民解放军第三军医大学 高免疫活性 CpG－S ODN 和拮抗 CpG－S ODN 作用的 CpG－N ODN 的基因序列及其应用
JP5331340B2 (ja) * 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
US7771731B2 (en) 2004-05-21 2010-08-10 Wyeth Llc Altered fibronectin-binding protein of Staphylococcus aureus
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
HUE026644T2 (en) 2004-05-28 2016-07-28 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
WO2006080946A2 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
JP2008506789A (ja) * 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
WO2006026470A2 (en) * 2004-08-27 2006-03-09 3M Innovative Properties Company Hiv immunostimulatory compositions
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP2149583B1 (de) 2004-09-24 2015-10-28 Novartis AG Modifiziertes VP1-Capsid Protein von Parvovirus B19
JP2008000001A (ja) * 2004-09-30 2008-01-10 Osaka Univ 免疫刺激オリゴヌクレオチドおよびその医薬用途
EP1796719B1 (de) 2004-10-06 2014-12-03 MedImmune, LLC Kühlschranktemperaturstabile grippeimpfstoff-zusammensetzungen
EP2808384B1 (de) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation der Replikationsrate durch Verwendung von seltener verwendeten synonymen Kodonen
JP2008515928A (ja) * 2004-10-08 2008-05-15 スリーエム イノベイティブ プロパティズ カンパニー Ｄｎａワクチンのためのアジュバント
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
BRPI0516974A (pt) 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006065549A2 (en) 2004-12-03 2006-06-22 Medical University Of Ohio Attenuated vaccine useful for immunizations against coccidioides spp. infections
EP1819364A4 (de) * 2004-12-08 2010-12-29 3M Innovative Properties Co Immunmodulatorische zusammensetzungen, kombinationen und verfahren
WO2006065751A2 (en) * 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US8197817B2 (en) 2004-12-17 2012-06-12 Dana-Farber Cancer Institute, Inc. Regulation of mink in thymocytes and T lymphocytes
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP1831226B1 (de) * 2004-12-30 2012-08-08 3M Innovative Properties Company Chirale tetracyklische verbindungen, die interferon biosyntheze induzieren
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
JP2008526765A (ja) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 皮膚転移の処置
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP4836145B2 (ja) * 2005-01-28 2011-12-14 クウォン，ヒュン−ジョ マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および／または正常免疫細胞保護用オリゴヌクレオチド
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
AU2006210392A1 (en) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2006091915A2 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
KR20070110901A (ko) 2005-03-04 2007-11-20 다이나박스 테크놀로지 코퍼레이션 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
WO2006107853A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1874325A2 (de) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP1871411A4 (de) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic Expression von hepatitis-b-virus-oberflächenantigen für impfstoffherstellung
CA2605808A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
US20090075342A1 (en) * 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
AU2006241149A1 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
CN101238145B (zh) 2005-06-14 2013-04-24 普罗陶克斯有限公司 修饰的成孔蛋白在制备治疗或预防良性前列腺增生的药物中的应用
AU2006265896B2 (en) 2005-06-30 2012-05-31 Archemix Corp. Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
SI2380584T1 (sl) 2005-07-01 2014-04-30 Index Pharmaceuticals Ab Imunostimulatorni postopek
PT2179737E (pt) 2005-07-01 2013-12-05 Index Pharmaceuticals Ab Método para modular a capacidade de resposta aos esteróides
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2007008904A2 (en) 2005-07-08 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
EP2614709A1 (de) 2005-07-18 2013-07-17 Novartis AG Kleintiermodell für HCV-Replikation
WO2007012285A1 (fr) * 2005-07-28 2007-02-01 Changchun Huapu Biotechnology Co., Ltd. Desoxynucleosides monocatenaires resistant aux infections virales
KR20080047463A (ko) * 2005-09-16 2008-05-28 콜리 파마슈티칼 게엠베하 뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
US20090214578A1 (en) * 2005-09-16 2009-08-27 Coley Pharmaceutical Gmbh Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
US20070081972A1 (en) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
EP1945247A1 (de) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
AU2006306805A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CN102864152B (zh) * 2005-11-07 2015-11-18 艾德拉药物股份有限公司 包含经修饰的免疫刺激性二核苷酸的基于寡核苷酸的化合物之免疫刺激特性
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
WO2007095316A2 (en) * 2006-02-15 2007-08-23 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
EP1988896A4 (de) 2006-02-22 2011-07-27 3M Innovative Properties Co Konjugate zur modifizierung von immunreaktionen
WO2007106536A2 (en) 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP2019686B1 (de) 2006-03-31 2012-07-11 Novartis AG Kombinierte mukosale und parenterale immunisierung gegen hiv
EP2017281A4 (de) 2006-04-14 2012-03-14 Kyowa Hakko Kirin Co Ltd Agonisten am toll-like receptor 9
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
DK2034015T3 (da) 2006-05-31 2012-10-15 Toray Industries Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf
WO2007143582A2 (en) * 2006-06-05 2007-12-13 Baylor College Of Medicine Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
US20100129403A1 (en) 2006-06-20 2010-05-27 Transgene S.A. Recombinant viral vaccine
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
DE102006050655A1 (de) * 2006-10-24 2008-04-30 Halmon Beheer B.V. Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen
EP2104738A2 (de) * 2006-10-26 2009-09-30 Coley Pharmaceuticals GmbH Oligoribonukleotide und ihre verwendung
EP3276349B1 (de) 2006-11-01 2019-08-07 Ventana Medical Systems, Inc. Haptene, haptenkonjugate, zusammensetzungen daraus und verfahren für ihre herstellung und verwendung
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
WO2008073661A2 (en) 2006-11-09 2008-06-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US20090285819A1 (en) * 2006-11-15 2009-11-19 Functional Genetics, Inc. Methods and compositions for treating influenza
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
WO2008127651A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
EP2377952A1 (de) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Verfahren zur Diagnostizierung und Behandlung von Astrozytoma
BRPI0811621A2 (pt) * 2007-05-17 2014-10-21 Coley Pharm Group Inc Oligonucleotídeos de classe a com potência imunoestimuladora, composição contendo os mesmos e uso da referida composição
SI2170353T1 (sl) * 2007-05-18 2015-09-30 Adiu Tide Pharmaceuticals Gmbh Fosfatno modificirani oligonukleotidni analogi z imunostimulatorno aktivnostjo
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
CN101678091A (zh) * 2007-05-24 2010-03-24 葛兰素史密丝克莱恩生物有限公司 冷冻干燥的抗原组合物
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US7879812B2 (en) 2007-08-06 2011-02-01 University Of Iowa Research Foundation Immunomodulatory oligonucleotides and methods of use therefor
US20090196915A1 (en) * 2007-08-21 2009-08-06 Gary Van Nest Composition and methods of making and using influenza proteins
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
CN101820908A (zh) * 2007-10-09 2010-09-01 科利制药公司 包含改性糖部分的免疫刺激寡核苷酸类似物
WO2009060440A1 (en) * 2007-11-05 2009-05-14 Mor Research Applications Ltd. Anti-measles cancer immunotherapy
CA2703519C (en) 2007-11-09 2017-04-18 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
WO2009082664A2 (en) * 2007-12-21 2009-07-02 Wyeth Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
CN105055432A (zh) * 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
JP5721441B2 (ja) * 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
AU2009246169B2 (en) 2008-05-15 2015-01-22 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
EP2278979A4 (de) 2008-05-21 2012-09-26 Us Gov Health & Human Serv Verfahren zur behandlung von pneumokoniose mit oligodesoxynukleotiden
CA2979353C (en) 2008-06-05 2020-06-30 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
US20110136897A1 (en) * 2008-08-14 2011-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
EP2353008A2 (de) 2008-09-22 2011-08-10 Oregon Health and Science University Verfahren zum nachweis einer infektion mit mycobacterium tuberculosis
US9061001B2 (en) * 2008-10-16 2015-06-23 University Of Saskatchewan Combination adjuvant formulation
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
AU2009313615B2 (en) 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
US8329188B2 (en) * 2008-11-12 2012-12-11 Theraclone Sciences, Inc. Human M2e peptide immunogens
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
KR101329374B1 (ko) 2008-12-09 2013-11-14 콜레이 파마시티컬 그룹, 인코포레이티드 면역자극성 올리고뉴클레오타이드
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
CA2748788C (en) 2009-01-05 2021-02-09 Epitogenesis Inc. The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
JP5692933B2 (ja) 2009-03-23 2015-04-01 ナニアールエックス セラピューティックス インコーポレイテッド 免疫刺激ＨＩＶＴａｔ誘導体ポリペプチドによる腫瘍治療
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
KR101856462B1 (ko) 2009-03-25 2018-05-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
AU2010232490B2 (en) 2009-04-03 2016-08-11 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
EP2413951A4 (de) 2009-04-03 2015-05-20 Univ Duke Formulierung zur herbeiführung einer breit reaktiven neutralisierung von hiv-antikörpern
EP2419129A2 (de) 2009-04-14 2012-02-22 Novartis AG Zusammensetzungen zur immunisierung gegen staphylococcus aerus
AU2010239689A1 (en) * 2009-04-21 2011-11-03 Selecta Biosciences, Inc. Immunonanotherapeutics providing a Th1-biased response
DK2424562T3 (en) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
CA2765364C (en) 2009-06-15 2015-05-26 National University Of Singapore Influenza vaccine, composition, and methods of use
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
EP2451461A4 (de) 2009-07-06 2013-05-29 Ontorii Inc Neuartige nukleinsäure-prodrugs und verwendungsverfahren dafür
EP4183412B1 (de) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
CA2768343A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
EP2453903B1 (de) 2009-07-17 2016-08-17 Industry Academic Cooperation Foundation, Hallym University Immunstimulatorische zusammensetzung mit liposomgekapselten oligonukleotiden und epitopen
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
US8598327B2 (en) 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
NZ598557A (en) * 2009-08-18 2013-08-30 Baxter Int Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CN107617110A (zh) 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
KR101660578B1 (ko) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2776922A1 (en) 2009-10-07 2011-04-14 Uvic Industry Partnerships Inc. Vaccines comprising heat-sensitive transgenes
WO2011047340A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US8961989B2 (en) 2009-11-20 2015-02-24 Oregon Health & Science University Methods for producing an immune response to tuberculosis
SG181628A1 (en) 2009-12-22 2012-07-30 Celldex Therapeutics Inc Vaccine compositions
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
US8685416B2 (en) 2010-03-02 2014-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
WO2011109833A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
WO2011112599A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
EP2563367A4 (de) 2010-04-26 2013-12-04 Chimerix Inc Verfahren zur behandlung von retroviren-infektionen und entsprechende dosierungspläne
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
HRP20181039T1 (hr) 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
EP3626263A1 (de) 2010-06-04 2020-03-25 Wyeth LLC Impstoffformulierungen
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2811103C (en) 2010-09-14 2020-01-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
EP2640190A4 (de) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modifizierte nikotinische verbindungen und zugehörige verfahren
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2468866A1 (de) * 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologisch aktive Oligonukleotide zur Modulation des Immunsystems
HUE033072T2 (hu) 2010-12-22 2017-11-28 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
SI2654785T1 (sl) 2010-12-22 2019-06-28 Bayer Intellectual Property Gmbh Ojačan imunski odziv pri govejih vrstah
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
EP2471926A3 (de) * 2010-12-30 2012-07-11 Intervet International BV Immunstimulierende Oligodeoxynukleotide
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
AU2012214148A1 (en) 2011-02-11 2013-08-29 Baxter Healthcare S.A. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US9315814B2 (en) * 2011-05-26 2016-04-19 Intervet Inc. Immunostimulatory oligodeoxynucleotides
BR112013030894A2 (pt) 2011-06-01 2016-08-16 Janus Biotherapeutics Inc moduladores do sistema imune
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
EP3153180A1 (de) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunktionale binder mit polyethylenglykolsegmenten und daraus hergestellte immunantwort-modifizierende konjugate
BR112013031028A2 (pt) 2011-06-03 2016-11-29 3M Innovative Properties Co conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
AU2012271336B2 (en) 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
EP2721158B1 (de) 2011-06-20 2017-05-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Rechnerisch optimierte breit reaktive h1n1-influenza-antigene
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
WO2013007703A1 (en) * 2011-07-08 2013-01-17 Universität Zürich CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US20140348865A1 (en) 2011-09-12 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. Immunogens based on an hiv-1 v1v2 site-of-vulnerability
EP2755683B1 (de) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Verfahren zur herstellung von saccharidprotein-glykokonjugaten
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
WO2013049535A2 (en) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Influenza vaccine
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
EP3269728B1 (de) 2011-10-20 2020-12-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services E-glycoprotein-polypeptide des dengue-virus mit mutationen zur eliminierung von immundominanten kreuzreaktiven epitopen
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
US20140086849A1 (en) 2012-09-21 2014-03-27 Elizabeth McKenna Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof
SG10202013014RA (en) 2012-01-16 2021-02-25 Mckenna Elizabeth Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
SG11201404653UA (en) 2012-02-07 2014-09-26 Univ Pittsburgh Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
CA2863949C (en) 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
CN104321335A (zh) 2012-02-24 2015-01-28 诺华股份有限公司 菌毛蛋白质和组合物
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA2866185C (en) 2012-03-23 2021-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
SG10201608980YA (en) 2012-04-26 2016-12-29 Novartis Ag Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
EP2852414B9 (de) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningokokken-serogruppe-x-konjugat
JP6216371B2 (ja) 2012-05-23 2017-10-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用
CN104428008B (zh) 2012-05-24 2020-10-09 美国政府(由卫生和人类服务部的部长所代表) 多价脑膜炎球菌缀合物及制备缀合物的方法
WO2013192144A2 (en) 2012-06-19 2013-12-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Rift valley fever virus replicon particles and use thereof
US9957969B2 (en) 2012-06-19 2018-05-01 Volvo Lastvagnar Ab Device for controlling a gas flow, an exhaust aftertreatment system and a system for propelling a vehicle
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2869842A1 (de) 2012-07-06 2015-05-13 Novartis AG Immunogene zusammensetzungen und verwendungen davon
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
CA2879443A1 (en) 2012-07-19 2014-01-23 Zoetis Llc Bovine influenza virus compositions
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
PT2885007T (pt) 2012-08-16 2018-12-10 Pfizer Processos e composições de glicoconjugação
EP2892549A1 (de) 2012-09-04 2015-07-15 Bavarian Nordic A/S Verfahren und zusammensetzungen zur verbesserung von impfstoffimmunreaktionen
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
US9562066B2 (en) * 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
CN104582718B (zh) 2012-10-03 2017-10-24 诺华股份有限公司 免疫原性组合物
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
TWI465241B (zh) 2012-12-19 2014-12-21 Ind Tech Res Inst 圓柏（Ｊｕｎｉｐｅｒｕｓ ｃｈｉｎｅｎｓｉｓ）萃取物或木酚素（ｌｉｇｎａｎ）用於製造抑制血管新生之藥物的用途
RU2672053C2 (ru) 2012-12-20 2018-11-09 Пфайзер Инк. Способ гликоконъюгации
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたｂ型肝炎コアポリペプチド
EP4272750A3 (de) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Proteinantigene zum schutz gegen pneumokokkenkolonisation und/oder -befall
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
EP2968510B1 (de) 2013-03-14 2019-10-09 President and Fellows of Harvard College Zusammensetzungen von nanopartikeln
CA2907098A1 (en) 2013-03-15 2014-09-25 Zoetis Services Llc Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
JP2016518126A (ja) 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ローンスターウイルス
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
CN103550783A (zh) * 2013-04-27 2014-02-05 中国人民解放军军事医学科学院放射与辐射医学研究所 一种核酸类药物靶向递送系统及其制备方法
CN112999344A (zh) 2013-05-15 2021-06-22 阿尔伯达大学董事会 E1e2 hcv疫苗及使用方法
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
TWI535451B (zh) * 2013-07-19 2016-06-01 財團法人國家衛生研究院 CpG寡去氧核苷酸、包含其之免疫組合物及組合物用於製備治療以刺激免疫反應的藥物之用途
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EP3024476A1 (de) 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
ES2957209T3 (es) 2013-09-30 2024-01-15 Triad Nat Security Llc Polipéptidos inmunogénicos mosaicos del VIH de región conservada
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
EP3524262A1 (de) 2013-11-01 2019-08-14 Pfizer Inc Vektoren zur expression von prostataassoziierten antigenen
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
ES2895977T3 (es) 2013-11-28 2022-02-23 Bavarian Nordic As Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
WO2015126502A2 (en) 2013-12-03 2015-08-27 Northwestern University Liposomal particles, methods of making same and uses thereof
WO2015089469A1 (en) 2013-12-13 2015-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multi-epitope tarp peptide vaccine and uses thereof
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP3095461A4 (de) * 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
WO2015108046A1 (ja) * 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095459A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
EP3094728B1 (de) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chirales design
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015112485A1 (en) 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
FI3583947T3 (fi) 2014-01-21 2023-10-12 Pfizer Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
EP3104877B1 (de) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9-impfstoff und verfahren zur verwendung davon
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
GB2523187A (en) 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
EP3116539B1 (de) 2014-03-11 2018-10-10 Regents of the University of Minnesota Impfstoffe gegen porzines epidemisches diarrhoevirus und verfahren zur verwendung davon
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
MX377794B (es) 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
US10111948B2 (en) 2014-04-25 2018-10-30 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
WO2015179851A1 (en) * 2014-05-23 2015-11-26 CAUCHON, Gregory Coating method and materials
EP3149479A2 (de) 2014-05-30 2017-04-05 Sanofi Pasteur Inc. Expression und konformationelle analyse von manipuliertem influenza-hämagglutinin
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3160453A1 (de) 2014-06-25 2017-05-03 Selecta Biosciences, Inc. Verfahren und zusammensetzungen zur behandlung mit synthetischen nanoträgern und immun-checkpoint-hemmern
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
US20170275287A1 (en) 2014-08-22 2017-09-28 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
BR112017007012A2 (pt) 2014-10-06 2018-03-06 Exicure Inc compostos anti-tnf
US20160129097A1 (en) * 2014-11-06 2016-05-12 Jeremy Delk Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
JP6536964B2 (ja) * 2014-12-26 2019-07-03 国立研究開発法人医薬基盤・健康・栄養研究所 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
HUE053145T2 (hu) 2014-12-31 2021-06-28 Checkmate Pharmaceuticals Inc Kombinált tumor immunterápia
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
MX391930B (es) 2015-01-16 2025-03-21 Zoetis Services Llc Vacuna contra la fiebre aftosa.
EP3256608A4 (de) 2015-02-13 2019-02-20 Icahn School of Medicine at Mount Sinai Rna-haltige zusammensetzungen und verfahren zu deren verwendung
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP6570648B2 (ja) 2015-03-12 2019-09-04 ゾエティス・サービシーズ・エルエルシー ピオリシン方法及び組成物
KR102143534B1 (ko) 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
EP3294324A1 (de) 2015-05-13 2018-03-21 Agenus Inc. Impfstoffe zur behandlung und prävention von krebs
WO2016196846A2 (en) 2015-06-02 2016-12-08 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
US10927151B2 (en) 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US11305002B2 (en) 2015-06-09 2022-04-19 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for Haemophilus influenzae
DK3307878T3 (da) 2015-06-10 2021-10-11 Us Health Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
EP3301179B1 (de) * 2015-07-09 2019-06-05 National Institute for Materials Science Immunstimulierender oligonukleotidkomplex
KR20250058066A (ko) 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US20190030153A1 (en) 2015-07-22 2019-01-31 University Of Saskatchewan Mycoplasma vaccines and uses thereof
TW201718001A (zh) 2015-07-31 2017-06-01 拜耳動物保健有限公司 豬物種中增強之免疫反應
DK3334454T3 (da) 2015-08-14 2022-11-14 Zoetis Services Llc Mycoplasma-Bovis-sammensætninger
CN107921113B (zh) 2015-08-25 2026-08-11 巴比塔·阿格拉沃尔 免疫调节组合物及其使用方法
EP3344276B1 (de) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptidinhibitoren von clostridium-difficile-toxin tcdb
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
EP3349717A4 (de) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. Ansätze zur verbesserung der hauthydrierung oder -befeuchtung
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
EP3359651A1 (de) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Stamm des menschlichen rota-virus g9p[6] und verwendung als impfstoff
CN117229414A (zh) 2015-10-08 2023-12-15 艾伯塔大学理事会 丙型肝炎病毒e1/e2异二聚体及其生产方法
CA3002685A1 (en) 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of her2-expressing solid tumors
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
WO2017129765A1 (en) 2016-01-29 2017-08-03 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
WO2017189448A1 (en) 2016-04-25 2017-11-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bivalent immunogenic conjugate for malaria and typhoid
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
EP3464328A1 (de) 2016-06-02 2019-04-10 Sanofi Pasteur Inc. Manipulierte influenza-antigen-polypeptide und immunogene zusammensetzungen davon
EP3464327A1 (de) 2016-06-03 2019-04-10 Sanofi Pasteur Inc. Modifizierung von manipulierten influenza-hämagglutinin-polypeptide
CA3026807A1 (en) 2016-06-13 2017-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
EP3474890B1 (de) 2016-06-22 2026-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
WO2018009604A1 (en) 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
WO2018009603A1 (en) 2016-07-08 2018-01-11 The United State of America, as represented by the Secretary, Department of Health and Human Service Chimeric west nile/zika viruses and methods of use
EP3493837B1 (de) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Polyvalente pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
US11224652B2 (en) 2016-08-05 2022-01-18 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10182146B2 (en) * 2016-08-22 2019-01-15 Nice Ltd. System and method for dynamic redundant call recording
EP3504239B1 (de) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intervalldosierung eines anti-csf-1r-antikörpers in kombination mit makrophagenaktivierungsmittel
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10172933B2 (en) 2016-10-31 2019-01-08 The United States Of America, As Represented By The Secretary Of Agriculture Mosaic vaccines for serotype a foot-and-mouth disease virus
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US11623945B2 (en) 2017-02-06 2023-04-11 The United States Of America, As Represented By The Secretary Of Agriculture Immunostimulating compositions and uses therefore
CN110392690B (zh) 2017-02-24 2024-01-30 默沙东有限责任公司 肺炎球菌缀合物疫苗制剂
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
WO2018183666A1 (en) 2017-03-31 2018-10-04 Boston Medical Center Corporation Methods and compositions using highly converved pneumococcal surface proteins
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018231706A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
WO2019018744A1 (en) 2017-07-21 2019-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
HUE068482T2 (hu) 2017-09-07 2025-01-28 Merck Sharp & Dohme Llc Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
WO2019048632A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
WO2019066571A2 (ko) 2017-09-28 2019-04-04 연세대학교 산학협력단 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
US11235046B2 (en) 2017-11-04 2022-02-01 Nevada Research & Innovation Corporation Immunogenic conjugates and methods of use thereof
EP3720483B1 (de) 2017-12-06 2025-11-19 Merck Sharp & Dohme LLC Zusammensetzungen enthalten streptococcus pneumoniae polysaccharide-protein konjugate und deren verwendung
US11116830B2 (en) 2017-12-18 2021-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
JP2021506851A (ja) 2017-12-19 2021-02-22 マサチューセッツ インスティテュート オブ テクノロジー 抗原−アジュバントカップリング試薬および使用の方法
WO2019143955A1 (en) 2018-01-22 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly protective inactivated influenza virus vaccine
BR112020015696A2 (pt) 2018-02-05 2020-12-08 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
WO2019152921A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
KR102787353B1 (ko) * 2018-03-02 2025-03-26 엘리시오 테라퓨틱스, 인크. 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
EP3774884B1 (de) 2018-03-28 2023-12-06 Sanofi Pasteur Inc. Verfahren zur erzeugung von breit schützenden impfstoffzusammensetzungen mit hämagglutinin
JP2021519600A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性インフルエンザ−フェリチンポリペプチド
EP3773698A1 (de) 2018-04-03 2021-02-17 Sanofi Ferritinproteine
CN112584858A (zh) 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
US11525010B2 (en) 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
AU2019274654B2 (en) 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
EP3574915A1 (de) 2018-05-29 2019-12-04 Neovacs Immunogenes produkt mit il-4 und/oder il-13 zur behandlung von erkrankungen im zusammenhang mit aberranter il-4- und/oder il-13-expression oder -aktivität
WO2020014656A1 (en) 2018-07-13 2020-01-16 University Of Georgia Research Foundation Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
CN110004150B (zh) * 2018-08-01 2023-03-10 中国农业科学院兰州兽医研究所 一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3119857A1 (en) 2018-11-16 2020-05-22 Versitech Limited Live attenuated influenza b virus compositions methods of making and using thereof
CA3120324A1 (en) 2018-12-04 2020-06-11 The Rockefeller University Hiv vaccine immunogens
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
WO2020123777A1 (en) 2018-12-12 2020-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
EP3894429B1 (de) 2018-12-14 2024-02-21 University of Georgia Research Foundation, Inc. Replikon-partikel des krim-kongo-fiebervirus und deren verwendung
EP3897705A2 (de) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Zusammensetzungen mit polysaccharidproteinkonjugaten von streptococcus pneumoniae und verfahren zu deren verwendung
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
JP7657727B2 (ja) 2019-04-02 2025-04-07 サノフイ 抗原性多量体呼吸器合胞体ウイルスポリペプチド
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3966331A4 (de) * 2019-05-10 2023-07-05 Microbio (Shanghai) Co., Ltd. Dimere cpg-oligonukleotide zur verwendung bei der modulation von immunantworten
CA3143198A1 (en) * 2019-06-14 2020-12-17 G Tech Bio Llc Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
EP3999093A4 (de) 2019-07-19 2023-11-22 Merck Sharp & Dohme LLC Antigene glykoprotein-e-polypeptide, zusammensetzungen und verfahren zu deren verwendung
CN114222584A (zh) 2019-07-30 2022-03-22 辉宝动物保健公司 一种用于禽类粘膜施用的组合物
JP2022542316A (ja) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
JP7698317B2 (ja) 2019-08-30 2025-06-25 ユニバーシティ オブ ロチェスター がん治療のためのセプチン阻害剤
AU2020351168A1 (en) 2019-09-18 2022-04-14 Children's Medical Center Corporation An anaplastic lymphoma kinase (ALK) cancer vaccine and methods of use
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
AU2020375214B2 (en) 2019-11-01 2024-02-08 Pfizer Inc. Escherichia coli compositions and methods thereof
US12653875B2 (en) 2019-12-17 2026-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated Leishmania parasite vaccines with enhanced safety characteristics
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
US12691169B2 (en) 2020-01-10 2026-07-28 University Of Georgia Research Foundation, Inc. Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
WO2021154745A1 (en) 2020-01-27 2021-08-05 Oregon State University Gonorrhea subunit vaccine
EP4103225A2 (de) 2020-02-13 2022-12-21 The Board Of Trustees Of The University Of Illinois Impfstoff und verfahren zum detektieren und vorbeugen von filariasis
KR20220143910A (ko) 2020-02-23 2022-10-25 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
JP2023514825A (ja) 2020-02-26 2023-04-11 ヴェルシテック リミテッド コロナウイルス感染症に対するｐｄ－１ベースのワクチン
WO2021173907A1 (en) 2020-02-28 2021-09-02 Sanofi Pasteur, Inc. High dose influenza vaccine for pediatric subjects
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
EP4138894A4 (de) 2020-04-20 2024-06-26 The University of Saskatchewan Zusammensetzungen und verfahren zur vorbeugung, kontrolle und diagnose mykobakterieller infektionen
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
AU2021270347A1 (en) 2020-05-11 2022-12-15 Erytech Pharma Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
EP4203995A1 (de) 2020-08-26 2023-07-05 Pfizer Inc. Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
US20230364232A1 (en) 2020-09-17 2023-11-16 Neovacs IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
EP4217387A2 (de) 2020-09-24 2023-08-02 Fred Hutchinson Cancer Center Gegen sox2-antigene gerichtete immuntherapie
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2022169835A1 (en) 2021-02-03 2022-08-11 The Board Of Trustees Of The University Of Illinois Vaccine and methods for preventing filariasis and dirofilariasis
EP4329786A4 (de) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Onkolytische viren zur modifizierten mhc-expression
JP7714690B2 (ja) 2021-05-28 2025-07-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022261251A1 (en) 2021-06-08 2022-12-15 Glyde Bio Inc. Immunogenic compositions comprising tumour-associated antigen
EP4104830A1 (de) 2021-06-16 2022-12-21 Burghardt Wittig Sequentielle angeborene und adaptive immunmodulation zur krebsbehandlung
WO2023277761A1 (en) * 2021-06-28 2023-01-05 Gunnar Pejler New use of monensin
WO2023288263A1 (en) 2021-07-16 2023-01-19 The Board Of Trustees Of The University Of Illinois Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
US20240335525A1 (en) 2021-08-11 2024-10-10 Sanofi Pasteur Inc. Truncated influenza neuraminidase and methods of using the same
AU2022361432A1 (en) 2021-10-08 2024-05-23 Sanofi Pasteur Inc. Multivalent influenza vaccines
CZ309696B6 (cs) * 2021-10-20 2023-08-02 Ústav organické chemie a biochemie AV ČR, v. v. i. Neizosterní izopolární fosfonátové analogy fosforothioátového CpG oligonukleotidu ODN2006
MX2024005482A (es) 2021-11-05 2024-05-22 Sanofi Sa Vacunas hibridas multivalentes antigripales que comprenden hemaglutinina y neuraminidasa y metodos de uso de las mismas.
WO2023081798A1 (en) 2021-11-05 2023-05-11 Sanofi Pasteur Inc. Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
AR127808A1 (es) 2021-11-30 2024-02-28 Sanofi Pasteur Inc Vacunas contra el metapneumovirus humano
JP2024544054A (ja) 2021-11-30 2024-11-27 サノフィ パスツール インコーポレイテッド ヒトメタニューモウイルスのウイルスベクターに基づくワクチン
CA3242439A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
JP2025508749A (ja) 2022-01-13 2025-04-10 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
JP2025503207A (ja) 2022-01-27 2025-01-30 サノフィ・パスツール 修飾されたＶｅｒｏ細胞、及びウイルス産生にこれを使用する方法
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250191693A1 (en) 2022-03-14 2025-06-12 Sanofi Pasteur, Inc. Machine-learning techniques in protein design for vaccine generation
US20250161295A1 (en) 2022-04-15 2025-05-22 Yale University Exatecan formulation
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
US20250312433A1 (en) 2022-05-11 2025-10-09 Pfizer Inc. Process for Producing of Vaccine Formulations With Preservatives
IL317745A (en) 2022-06-29 2025-02-01 Bavarian Nordic As Modified recombinant SARNA (VRP) and Vaccinia Ankara virus (MVA) prime regimen
KR20250054810A (ko) 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
KR20250099727A (ko) 2022-11-04 2025-07-02 사노피 파스퇴르 인크 호흡기 세포융합 바이러스 rna 백신접종
AU2023377159A1 (en) 2022-11-10 2025-03-06 Université Libre de Bruxelles Group a streptococcus vaccine antigen
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (de) 2022-11-22 2025-10-01 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
CN120513083A (zh) 2022-12-01 2025-08-19 辉瑞大药厂 肺炎链球菌缀合物疫苗制剂
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
AU2023393199A1 (en) 2022-12-13 2025-05-29 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
TW202438514A (zh) 2022-12-20 2024-10-01 法商賽諾菲公司 鼻病毒mrna疫苗
AU2024208643A1 (en) 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024163327A1 (en) 2023-01-30 2024-08-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252779A1 (es) 2023-04-14 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL324411A (en) 2023-05-05 2026-01-01 Sanofi Pasteur Inc Preparations for use in the treatment of acne
US20250009865A1 (en) 2023-05-10 2025-01-09 Sanofi Combination respiratory mrna vaccines
EP4709418A1 (de) 2023-05-11 2026-03-18 Sanofi Pasteur Inc. Impfstoff gegen das respiratorische synzytialvirus und verfahren zur verwendung
CN121263203A (zh) 2023-05-19 2026-01-02 葛兰素史克生物有限公司 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
JP2026518371A (ja) 2023-06-01 2026-06-05 サノフィ ワクチンズ ユーエス インコーポレイテッド Ｍｒｎａ脂質ナノ粒子を含む熱安定性組成物
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
IL325951A (en) 2023-07-19 2026-03-01 Sanofi Sa Porphyromonas gingivalis antigenic constructs
TW202527960A (zh) 2023-09-06 2025-07-16 美商賽諾菲巴斯德公司 經修飾ｂ型流感血球凝集素多肽及核酸及其用途
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025073874A1 (en) 2023-10-05 2025-04-10 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Vaccine composition comprising m2e nanoparticles and ha1 protein
TW202539728A (zh) 2023-11-16 2025-10-16 美商默沙東有限責任公司 肽共軛物疫苗組合物及治療阿茲海默氏症之方法
AU2024380679A1 (en) 2023-11-17 2026-07-02 Sanofi Vaccines US Inc. Trehalose vaccine formulation
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025186459A1 (en) 2024-03-08 2025-09-12 Sanofi Antigenic epstein barr virus polypeptides
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025210592A1 (en) 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Muscle cell lnp-mrna quality control assays
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
TW202610680A (zh) 2024-05-14 2026-03-16 美商輝瑞股份有限公司 鋁佐劑奈米粒子、其製造方法及其用途
TW202612726A (zh) 2024-06-12 2026-04-01 美商輝瑞股份有限公司 誘發針對困難梭狀芽孢桿菌的免疫反應之免疫原性組成物和方法
EP4670733A1 (de) 2024-06-27 2025-12-31 Sanofi Verfahren zur herstellung von viralen proteinen und deren verwendungen
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026052773A1 (en) 2024-09-06 2026-03-12 Sanofi Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof
WO2026104670A1 (en) 2024-11-15 2026-05-21 Sanofi Pasteur Variants of epstein-barr virus glycoprotein b, nucleic acids encoding the same, and uses thereof
WO2026139467A1 (en) 2024-12-23 2026-07-02 Institut National de la Santé et de la Recherche Médicale Methods for producing vesicles and applications thereof

Family Cites Families (524)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2010A (en) * 1841-03-18 Machine foe
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US2002A (en) * 1841-03-12 Tor and planter for plowing
US3521637A (en) * 1967-11-28 1970-07-28 Nelson J Waterbury Tampon or similar sanitary napkin containing vitamin a
US3627874A (en) 1969-07-16 1971-12-14 Merck & Co Inc Vaccine preparation
US3761585A (en) 1971-04-05 1973-09-25 Beecham Group Ltd Vaccines containing modified allergenic material
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
DE2643213C2 (de) * 1976-09-25 1985-02-21 Bayer Ag, 5090 Leverkusen Verfahren zum Abschwächen oder Inaktivieren von Mikroorganismen
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
EP0092574B1 (de) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonukleotides heilmittel und dessen herstellungsverfahren
ES8301593A1 (es) 1981-11-16 1983-01-01 Union Ind Y Agro Ganader S A U Procedimiento de obtencion de una leche humanizada adiciona-da de nucleotidos con destino a la alimentacion infantil.
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5059519A (en) 1986-07-01 1991-10-22 University Of Massachusetts Medical School Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
ES2007350A6 (es) 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
CA1339596C (en) 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5112605A (en) * 1989-03-17 1992-05-12 Genentech, Inc. Temporal gamma-interferon administration for allergies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5629158A (en) * 1989-03-22 1997-05-13 Cemu Bitecknik Ab Solid phase diagnosis of medical conditions
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5178860A (en) 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5786189A (en) 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
HUT63430A (en) 1990-08-16 1993-08-30 Isis Pharmaceuticals Inc Process for producing oligonucleotides influencing the effect of cytomegalovirus infection
US6042838A (en) * 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
CA2106386A1 (en) 1991-04-18 1992-10-19 Barbara C. F. Chu Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
US5498410A (en) * 1991-04-22 1996-03-12 Gleich; Gerald J. Method for the treatment of eosinophil-associated conditions with anionic polymers
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
WO1994008003A1 (en) 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
WO1992021353A1 (en) 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
US5582986A (en) 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
JPH07501525A (ja) 1991-11-15 1995-02-16 テンプル　ユニバーシティ　‐　オブ　ザ　コモンウェルス　システム　オブ　ハイヤー　エデュケーション ｃ−ｍｙｂプロトオンコジーンに対するアンチセンスオリゴヌクレオチドによる黒色腫の処置
EP0641353A4 (de) 1991-11-18 1997-07-02 Tanox Biosystems Inc Antisense-oligonukleotide für isotyp-spezifische unterdrückung der immunoglobinproduktion.
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
ATE219522T1 (de) 1992-02-04 2002-07-15 Chiron Corp Hepatistherapeutikum
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US6498147B2 (en) 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
US5726518A (en) * 1992-07-22 1998-03-10 Nikon Corporation Supporting device of relative moving element of vibration actuator or vibration motor
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
JPH08502723A (ja) 1992-07-27 1996-03-26 ハイブライドン インコーポレイテッド オリゴヌクレオチド・アルキルホスホノチオエート
US6107062A (en) * 1992-07-30 2000-08-22 Inpax, Inc. Antisense viruses and antisense-ribozyme viruses
WO1994004196A1 (en) 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
US5429199A (en) * 1992-08-26 1995-07-04 Kennametal Inc. Cutting bit and cutting insert
FI951600A7 (fi) 1992-10-05 1995-05-10 Hybridon Inc Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JP2950520B2 (ja) 1993-04-02 1999-09-20 アンティキャンサー インコーポレーテド 毛胞に有益な配合物を送達する方法
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
EP0707653B1 (de) 1993-06-11 2004-09-01 Commonwealth Scientific And Industrial Research Organisation Methode der spezifischen abschaltung von genen durch dna-methylierung
CA2165821C (en) * 1993-06-23 2002-01-08 Albert D. Friesen Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
ATE239787T1 (de) 1993-07-19 2003-05-15 Gen Probe Inc Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US6605708B1 (en) 1993-07-28 2003-08-12 Hybridon, Inc. Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US20030109469A1 (en) * 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
JPH09501936A (ja) 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO1995017507A1 (en) 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
US5712384A (en) 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5646126A (en) 1994-02-28 1997-07-08 Epoch Pharmaceuticals Sterol modified oligonucleotide duplexes having anticancer activity
EP0804249A2 (de) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeres system zur freisetzung von genen
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5696248A (en) 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU3133695A (en) 1994-07-18 1996-02-16 University Of North Carolina At Chapel Hill, The Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
AU3559695A (en) * 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
ATE219660T1 (de) * 1994-09-30 2002-07-15 Inex Pharmaceuticals Corp Mittel zum einbringen polyanionischer materialien in zellen
WO1996012008A1 (en) 1994-10-13 1996-04-25 Merck & Co., Inc. Synthesis of methylase-resistant genes
US6630455B1 (en) 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
EP0810882A4 (de) 1995-02-09 1999-05-19 Icn Pharmaceuticals Verfahren und zusammensetzung für die regulation der cd28-expression
US5932556A (en) 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
GB9505438D0 (en) 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
ATE210466T1 (de) * 1995-04-13 2001-12-15 Milkhaus Lab Inc Methoden zur behandlung von atemwegserkrankungen
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5858987A (en) * 1995-05-05 1999-01-12 Mitotix, Inc. E6AP antisense constructs and methods of use
ATE271128T1 (de) 1995-05-11 2004-07-15 Applied Research Systems Inhibitoren der il-6 aktivitaet
US5955059A (en) * 1995-06-06 1999-09-21 Trustees Of Boston University Use of locally applied DNA fragments
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US7034007B1 (en) * 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US5994315A (en) 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US5968909A (en) 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
US6667293B1 (en) * 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
BR9610802A (pt) 1995-10-04 1999-07-13 Immunex Corp Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
SE9600648D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US5843770A (en) 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US6620805B1 (en) 1996-03-14 2003-09-16 Yale University Delivery of nucleic acids by porphyrins
US6030955A (en) * 1996-03-21 2000-02-29 The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
US6121247A (en) 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
KR20000022445A (ko) 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
EP0819758B1 (de) 1996-07-16 2006-09-20 Archibald James Mixson Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
US5854418A (en) 1996-07-25 1998-12-29 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
DE19637223A1 (de) * 1996-09-13 1998-04-09 Beiersdorf Ag Wiederlösbare, selbstklebende Vorrichtung
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6562345B1 (en) * 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
SE9604296D0 (sv) 1996-11-22 1996-11-22 Astra Ab New pharmaceutical formulation of polypeptides
AU5720098A (en) 1996-12-27 1998-07-31 Icn Pharmaceuticals, Inc. G-rich oligo aptamers and methods of modulating an immune response
FR2757876B1 (fr) 1996-12-27 1999-04-09 Biovector Therapeutics Sa Conjuges d'un vecteur particulaire et d'oligonucleotides, leur procede de preparation et les compositions pharmaceutiques les contenant
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US20030064945A1 (en) * 1997-01-31 2003-04-03 Saghir Akhtar Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
GB9702021D0 (en) 1997-01-31 1997-03-19 Imperial College Medicaments
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2281838A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) * 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
JP2001526688A (ja) 1997-05-19 2001-12-18 メルク エンド カンパニー インコーポレーテッド オリゴヌクレオチドアジュバント
EP1003531B1 (de) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Verfahren zur Herstellung von Nukleinsäurekonstrukten
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1998055609A1 (en) * 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
ATE408422T1 (de) * 1997-07-03 2008-10-15 Donald E Macfarlane Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
WO1999005303A1 (en) 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
WO1999009154A2 (en) 1997-08-19 1999-02-25 Hybridon, Inc. Novel hiv-specific synthetic oligonucleotides and methods of their use
PT1009413E (pt) 1997-09-05 2007-05-31 Univ California Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
CN1285753A (zh) * 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
WO1999033493A1 (en) 1997-12-23 1999-07-08 Inex Pharmaceuticals Corporation Polyamide oligomers
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JPH11209289A (ja) * 1998-01-22 1999-08-03 Taisho Pharmaceut Co Ltd 粘膜免疫誘起剤
EP1061951B1 (de) 1998-02-25 2003-08-27 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp-ribosylating-exotoxin induzierten immunantwort
KR100593427B1 (ko) * 1998-03-12 2006-06-28 루사이트 인터내셔널 유케이 리미티드 폴리머 조성물
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
ATE331739T1 (de) 1998-04-28 2006-07-15 Inex Pharmaceuticals Corp Polyanionische polymere mit verbesserter fusogenfähigkeit
EP1077708A1 (de) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methoden zur preventiven und therapeutischen behandlung von parasitären infektionen und damit verbundener krankheiten mittels cpg oligonukleotiden
AU760795B2 (en) 1998-05-14 2003-05-22 Coley Pharmaceutical Gmbh Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6881561B1 (en) 1998-05-27 2005-04-19 Cheil Jedang Corporation Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
DE69919869T2 (de) 1998-06-10 2005-09-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Stimulierung des immunsystems
US6086898A (en) * 1998-06-23 2000-07-11 The Board Of Trustees Of The Leland Stanford Junior University Method of converting a Th2-type allergic immune response into a Th1-type immune response
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
ATE237312T1 (de) 1998-07-20 2003-05-15 Protiva Biotherapeutics Inc In liposomen verkapselte nukleinsäurekomplexe
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP0979869A1 (de) 1998-08-07 2000-02-16 Hoechst Marion Roussel Deutschland GmbH Kurze Oligonukleotide zur Hemmung von VEGF-Expression
US20010034330A1 (en) 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
ATE315405T1 (de) * 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
BR9913382A (pt) * 1998-08-20 2001-09-25 Du Pont Fragmentos de ácido nucléico isolados codificadores de uma enzima modificadora de ácidos graxos vegetais associada com a formação de uniões duplas conjugadas, genes quiméricos, células hospedeiras transformadas, sementes, óleos, métodos de alteração do nìvel de ácidos graxos com uniões duplas conjugadas em uma célula hospedeira, métodos de produção de óleo de sementes contendo ácidos graxos com uniões duplas conjugadas nas sementes de plantas, métodos de produção de enzimas modificadoras de ácidos graxos associadas com a formação de uniões duplas conjugadas, métodos de isolamento de fragmentos de ácidos nucléicos e seus subfragmentos funcionalmente equivalentes codificadores de uma enzima modificadora de ácidos graxos vegetais associada a formação de uniões duplas conjugadas, alimento animal, métodos de aprimoramento da qualidade de carcaça de um animal e complemento
WO2000014217A2 (en) 1998-09-03 2000-03-16 Coley Pharmaceutical Gmbh G-motif oligonucleotides and uses thereof
US20020065236A1 (en) * 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
FR2783170B1 (fr) 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
EP1671646A3 (de) 1998-09-18 2007-08-29 Dynavax Technologies Corporation Verfahren zur Behandlung von IgE- assoziierten Krankheiten und Zusammensetzungen zur Verwendung in diesen Verfahren
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
WO2000020039A1 (en) 1998-10-05 2000-04-13 The Regents Of The University Of California Methods and adjuvants for stimulating mucosal immunity
CA2344558A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
JP2003520568A (ja) 1999-02-02 2003-07-08 バイオカシェ ファーマシューティカルズ， インコーポレイテッド 高度な抗原提示プラットフォーム
US6887464B1 (en) 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
CA2361459A1 (en) 1999-02-05 2000-08-10 Salam Abdul Kadhim Use of cationic lipids to generate anti-tumor immunity
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
WO2000054803A2 (en) * 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
US6625426B2 (en) * 1999-03-22 2003-09-23 Ronald Baratono Combined rear view mirror and telephone
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (de) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
WO2000062787A1 (en) 1999-04-15 2000-10-26 The Regents Of The University Of California Methods and compositions for use in potentiating antigen presentation by antigen presenting cells
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
EP1177439B1 (de) 1999-04-29 2004-09-08 Coley Pharmaceutical GmbH Screening nach modulatoren der funktion von immunstimulatorischer dna
US6737066B1 (en) * 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
AP1891A (en) 1999-05-06 2008-09-23 The Immune Response Corp HIV immunogenic compositions and methods.
WO2000075304A1 (fr) 1999-06-08 2000-12-14 Aventis Pasteur Oligonucleotide immunostimulant
CA2412345A1 (en) 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
ES2250151T3 (es) 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Uso de cpg como adyuvante de vacuna contra vih.
GB9915204D0 (en) 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
FR2795963A1 (fr) * 1999-07-08 2001-01-12 Pasteur Merieux Serums Vacc Polynucleotide immunostimulant
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
DE60017259T2 (de) 1999-08-13 2005-12-08 Hybridon, Inc., Cambridge Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
US7479285B1 (en) 1999-08-19 2009-01-20 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US20050249794A1 (en) 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
US6395678B1 (en) * 1999-09-01 2002-05-28 Aero-Terra-Aqua Technologies Corporation Bead and process for removing dissolved metal contaminants
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
IL148844A0 (en) * 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
ES2411096T3 (es) * 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
DE60039715D1 (de) 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
WO2001039800A2 (en) * 1999-12-06 2001-06-07 The Board Of Trustees Of The University Of Arkansas Controlled delivery of antigens
WO2001045750A1 (en) 1999-12-21 2001-06-28 The Regents Of The University Of California Method for preventing an anaphylactic reaction
CA2397374A1 (en) 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
WO2001051500A1 (en) * 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
WO2001055370A2 (en) 2000-01-26 2001-08-02 Hybridon, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
JP2003529559A (ja) 2000-01-31 2003-10-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規用途
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805265B1 (fr) 2000-02-18 2002-04-12 Aventis Pasteur Oligonucleotides immunostimulants
US20030130217A1 (en) * 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
CA2399550A1 (en) 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
EP1261366A4 (de) 2000-02-24 2003-06-18 Univ Leland Stanford Junior Adjuvant-behandlung durch in vivo aktivierung dendritischer zellen
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US6851845B2 (en) * 2000-03-10 2005-02-08 The Maitland Company, Inc. Method and apparatus for processing waste material
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
CA2404041A1 (en) 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20020142978A1 (en) 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
US7524826B2 (en) 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
US6321873B1 (en) * 2000-04-21 2001-11-27 Tra-Lor-Mate, Inc. Ladder mounting system
AU2001257366B2 (en) 2000-05-01 2006-03-16 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2001085910A2 (en) * 2000-05-05 2001-11-15 The Regents Of The University Of California Agents that modulate dna-pk activity and methods of use thereof
WO2001085751A1 (en) 2000-05-09 2001-11-15 Reliable Biopharmaceutical, Inc. Polymeric compounds useful as prodrugs
DE60112073T2 (de) * 2000-05-12 2006-04-20 Pharmacia & Upjohn Co. Llc, Kalamazoo Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US6339630B1 (en) * 2000-05-18 2002-01-15 The United States Of America As Represented By The United States Department Of Energy Sealed drive screw operator
EP1292331A2 (de) 2000-06-07 2003-03-19 Biosynexus Incorporated Immunstimulierende rns/dns hybridmolekule
EP1296714B1 (de) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
US20020165178A1 (en) * 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
AU8640501A (en) 2000-07-31 2002-02-13 Univ Yale Innate immune system-directed vaccines
US20020198165A1 (en) * 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
DK1423528T3 (da) 2000-09-01 2008-05-13 Epigenomics Ag Fremgangsmåde til bestemmelse af methyleringsgraden af bestemte cytosiner i genomisk DNA i sekvenskonteksten 5-CPG-3
WO2002018631A2 (de) * 2000-09-01 2002-03-07 Epigenomics Ag Diagnose von bestehenden erkrankungen oder der prädisposition für bestimmte erkrankungen
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
EP1366077B1 (de) * 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US6787524B2 (en) * 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
EP2292632A3 (de) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation der immunostimulatorischen Aktivität von immunostimulierenden Oligonukleotidanaloga durch positionelle chemische Veränderungen
SE0003538D0 (sv) * 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
FR2814958B1 (fr) 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
ATE534401T1 (de) * 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe
AU2002214868A1 (en) 2000-11-02 2002-05-15 Inex Pharmaceuticals Corporation Therapeutic oligonucleotides of reduced toxicity
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
CA2430206A1 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
EP1364010B1 (de) * 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US7337306B2 (en) * 2000-12-29 2008-02-26 Stmicroelectronics, Inc. Executing conditional branch instructions in a data processor having a clustered architecture
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20030129605A1 (en) 2001-05-04 2003-07-10 Dong Yu Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages
EP2545937A1 (de) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsionsimpfstoffe
JP2005509591A (ja) 2001-06-15 2005-04-14 リバファーム・インコーポレイテッド ヌクレオシドワクチンアジュバント
KR100985457B1 (ko) 2001-06-21 2010-10-06 다이나박스 테크놀로지 코퍼레이션 키메라 면역조절 화합물 및 그것들의 사용 방법
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20040132677A1 (en) 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
WO2003000232A2 (en) 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides
US20030003970A1 (en) 2001-06-28 2003-01-02 Alan Johnson Portable communications device
AU2002322358B2 (en) 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
US6982033B2 (en) * 2001-07-13 2006-01-03 Donald Hubbard H Aerobic treatment plant with filter pipe
WO2003040308A2 (en) 2001-07-27 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
AU2002326561B2 (en) * 2001-08-07 2008-04-03 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
CA2456201A1 (en) 2001-08-10 2003-02-27 Dynavax Technologies Corporation Immunomodulatory oligonucleotide formulations and methods for use thereof
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EA007232B1 (ru) * 2001-08-17 2006-08-25 Коли Фармасьютикал Гмбх Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
CA2458876A1 (en) 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
WO2004012669A2 (en) 2002-08-01 2004-02-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
AU2002353783A1 (en) * 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
DE60234782D1 (de) 2001-09-28 2010-01-28 Purdue Research Foundation Behandlungsverfahren mit liganden-immunogenkonjugaten
WO2003031573A2 (en) * 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
KR20050048539A (ko) 2001-10-06 2005-05-24 메리얼엘엘씨 ＣｐＧ 제제 및 관련된 방법
AU2002346960A1 (en) 2001-10-06 2003-04-22 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
AU2002360278A1 (en) * 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2003039595A2 (en) 2001-11-07 2003-05-15 Inex Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
DK1719511T3 (da) 2001-11-16 2009-04-14 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
CA2469082A1 (en) * 2001-12-04 2003-06-12 Raj K. Puri Chimeric molecule for the treatment of th2-like cytokine mediated disorders
DE10161755B4 (de) * 2001-12-15 2005-12-15 Infineon Technologies Ag Kontaktstift zum Testen mikroelektronischer Bauteile mit kugelförmigen Kontakten
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US20060210555A1 (en) 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20030232443A1 (en) 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
CA2480176A1 (en) * 2002-04-11 2003-10-23 Zymogenetics, Inc. Use of interleukin-24 to treat ovarian cancer
CN101160399A (zh) * 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 寡核苷酸组合物及其在调节免疫应答中的应用
US6948271B2 (en) * 2002-05-06 2005-09-27 Innovative Supply, Inc. Identification and tracking system for deceased bodies
JP2005524963A (ja) * 2002-05-08 2005-08-18 ダナ・コーポレーション プラズマ触媒
US20040009944A1 (en) 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
EP1505942B1 (de) 2002-05-10 2008-08-13 Tekmira Pharmaceuticals Corporation Pathogene impstoffe und verfahren zur deren verwendung
CA2485400A1 (en) 2002-05-10 2003-11-20 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
AU2003246396B2 (en) 2002-05-28 2008-08-21 Merck Patent Gmbh A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
WO2003103586A2 (en) * 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040013688A1 (en) * 2002-07-03 2004-01-22 Cambridge Scientific, Inc. Vaccines to induce mucosal immunity
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en) 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
CN1468957A (zh) 2002-07-19 2004-01-21 中国人民解放军第二军医大学 一种用作人用治疗性疫苗佐剂的质粒
US20050209183A1 (en) 2002-07-25 2005-09-22 Phenion Gmbh & Co. Kg Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs
EP1393745A1 (de) 2002-07-29 2004-03-03 Hybridon, Inc. Modulierung der immunstimulierenden Eigenschaften von Oligonukleotiden und Analoga durch optimale Darstellung der 5'-Enden
US7884083B2 (en) * 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US6928476B2 (en) * 2002-08-23 2005-08-09 Mirra, Inc. Peer to peer remote data storage and collaboration
US6744084B2 (en) * 2002-08-29 2004-06-01 Micro Technology, Inc. Two-transistor pixel with buried reset channel and method of formation
SI1572095T1 (sl) * 2002-09-13 2015-12-31 Novartis Ag Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv
US6994870B2 (en) * 2002-09-18 2006-02-07 Jaw-Ji Tsai Local nasal immunotherapy with allergen strip for allergic rhinitis
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003278845A1 (en) 2002-09-19 2004-04-08 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
US6988995B2 (en) * 2002-09-30 2006-01-24 Carl Zeiss Meditec, Inc. Method and system for detecting the effects of Alzheimer's disease in the human retina
US8043622B2 (en) * 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2003304107B2 (en) * 2002-11-01 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
WO2004041183A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
US7956043B2 (en) * 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
KR100525321B1 (ko) 2002-12-13 2005-11-02 안웅식 파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
DK1992635T3 (da) 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
US7625872B2 (en) 2002-12-23 2009-12-01 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
JP4726630B2 (ja) 2003-01-16 2011-07-20 イデラ ファーマシューティカルズ インコーポレイテッド 修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
US7189781B2 (en) * 2003-03-13 2007-03-13 H.B. Fuller Licensing & Finance Inc. Moisture curable, radiation curable sealant composition
ES2351489T3 (es) 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
EP1608403A2 (de) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
WO2004094671A2 (en) 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
JP3887346B2 (ja) * 2003-04-28 2007-02-28 株式会社東芝 映像信号処理装置及び映像信号処理方法、映像表示装置
KR20060012622A (ko) 2003-05-16 2006-02-08 하이브리돈, 인코포레이티드 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
EP1484336A1 (de) * 2003-06-02 2004-12-08 Pevion Biotech Ltd. Methode zur Herstellung von konformationseingeschränkten Peptiden, Peptidomimetika und deren Verwendung als synthetische Vaccine
JP4874801B2 (ja) 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
CA2528883A1 (en) * 2003-06-13 2004-12-23 Daiichi Asubio Pharma Co., Ltd. Pharmaceutical compositions for preventing or treating th1-mediated immune diseases
JP5127224B2 (ja) * 2003-06-17 2013-01-23 マンカインド コーポレイション 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
US7410975B2 (en) * 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
US20040265833A1 (en) 2003-06-23 2004-12-30 Cathy Lofton-Day Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
AU2004255470B2 (en) 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
CA2530062A1 (en) 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
MXPA06000619A (es) 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
OA13246A (en) 2003-08-28 2007-01-31 Immune Response Corp Inc Immunogenic HIV Compositions and related methods.
EP1667694B1 (de) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7-liganden zur behandlung von hepatitis c
WO2005023289A1 (ja) 2003-09-08 2005-03-17 Intellectual Property Consulting Incorporated 慢性ｃ型肝炎を治療するための医薬組成物
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005027920A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
CA2542099A1 (en) 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050087538A1 (en) * 2003-10-23 2005-04-28 Wolfe Darrell R. Iceless multiple can cooler
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
NZ546275A (en) 2003-10-30 2009-05-31 Coley Pharm Gmbh C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
JP4088246B2 (ja) * 2003-12-05 2008-05-21 富士通株式会社 リングネットワークのマスタ設定方法及び装置
KR101138131B1 (ko) 2003-12-08 2012-04-23 이데라 파마슈티칼즈, 인코포레이티드 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US20070172315A1 (en) * 2003-12-18 2007-07-26 Barrett Robert K Method and Apparatus for Creating Soil or Rock Subsurface Support
EP1550458A1 (de) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergisitische liposomale Adjuvantien
KR100558851B1 (ko) 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
WO2005076975A2 (en) * 2004-02-06 2005-08-25 Mayo Foundation For Medical Education And Research Complexed polypeptide and adjuvant for improved vaccines
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
JP2007526253A (ja) 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
EP1716234B1 (de) 2004-02-20 2013-10-02 Mologen AG Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren
CA2557443A1 (en) 2004-03-12 2005-09-29 Hybridon, Inc. Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
JP2007531746A (ja) * 2004-04-02 2007-11-08 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｉｌ−１０応答を誘導するための免疫活性化核酸
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
WO2005115449A1 (en) * 2004-05-28 2005-12-08 Alk-Abelló A/S Method of treating allergy and infection by eliciting an iga antibody response
US8399025B2 (en) * 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
WO2006080946A2 (en) 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
US7756043B1 (en) * 2004-06-09 2010-07-13 Sprint Communications Company L.P. Method for identifying high traffic origin-destination node pairs in a packet based network
US7498425B2 (en) 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
BRPI0512110A (pt) 2004-06-15 2007-10-23 Idera Pharmaceutical Inc multìmeros de oligonucleotìdeos imunoestimulatórios
WO2006000215A1 (en) * 2004-06-25 2006-01-05 Tc Electronic A/S Method of evaluating perception intensity of an audio signal and a method of controlling an input audio signal on the basis of the evaluation
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
EP1776105A2 (de) * 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Verfahren und zusammensetzungen zur induzierung eigener immunantworten
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
US20060058261A1 (en) * 2004-09-15 2006-03-16 Andre Aube Chitin derivatives for hyperlipidemia
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR100721928B1 (ko) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
WO2006053090A2 (en) 2004-11-08 2006-05-18 Idera Pharmaceuticals Synergistic inhibition of vegf and modulation of the immune response
WO2006072251A1 (en) 2005-01-07 2006-07-13 Alk-Abellò A/S Method of preventive treatment of allergy by oromucosal administration of an allergy vaccine
WO2006091915A2 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1874325A2 (de) 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
AU2006241149A1 (en) 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US7325152B2 (en) * 2005-06-30 2008-01-29 Infineon Technologies Ag Synchronous signal generator
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
EP1929014B1 (de) * 2005-08-31 2014-08-13 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Verfahren zur änderung einer durch cpg-oligodesoxynukleotide des d-typen induzierten immunantwort
US20090214578A1 (en) 2005-09-16 2009-08-27 Coley Pharmaceutical Gmbh Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
KR20080047463A (ko) 2005-09-16 2008-05-28 콜리 파마슈티칼 게엠베하 뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
WO2007038720A2 (en) 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
EA200801045A1 (ru) * 2005-10-12 2008-10-30 Кэнсер Рисерч Текнолоджи Лтд. Способы и композиции для лечения иммунных нарушений
US20070093439A1 (en) 2005-10-25 2007-04-26 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
AU2006306805A1 (en) * 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US20070243209A1 (en) * 2005-10-28 2007-10-18 Health Research, Inc. Compositions and methods for prevention and treatment of fungal diseases
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
EP1942945B1 (de) 2005-11-07 2011-10-19 Idera Pharmaceuticals Immunstimulatorische Eigenschaften von Verbindungen auf Oligonukleotid-basis mit modifizierten immunstimulatorischen Dinukleotiden
MX2008006004A (es) 2005-11-07 2008-10-01 Idera Pharmaceuticals Inc Propiedades inmunoestimuladoras de compuestos a base de oligonucleotidos que comprenden dinucleotidos inmunoestimuladores modificados.
US7776834B2 (en) 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
WO2007062107A2 (en) * 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
EP1962909A4 (de) 2005-12-20 2012-04-18 Idera Pharmaceuticals Inc Immunstimulierende aktivität palindromischer immunmodulierender oligonukleotide mit palindromischen segmenten verschiedener länge
WO2007095316A2 (en) * 2006-02-15 2007-08-23 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
WO2008019018A2 (en) * 2006-08-03 2008-02-14 William Soo Hoo Bioactive molecular matrix and methods of use in the treatment of disease
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
WO2008019486A1 (en) * 2006-08-16 2008-02-21 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
EP2468300B1 (de) * 2006-09-26 2017-12-20 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen Adjuvans
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20100189772A1 (en) 2006-09-27 2010-07-29 Coley Pharmaceutical Group, Inc Compositions of TLR ligands and antivirals
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
EP2104738A2 (de) * 2006-10-26 2009-09-30 Coley Pharmaceuticals GmbH Oligoribonukleotide und ihre verwendung
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
AU2007329375A1 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
BRPI0811621A2 (pt) 2007-05-17 2014-10-21 Coley Pharm Group Inc Oligonucleotídeos de classe a com potência imunoestimuladora, composição contendo os mesmos e uso da referida composição
EP2591787A1 (de) * 2007-08-13 2013-05-15 Pfizer Inc Kombinations-motif-immunstimulierende Oligonukleotide mit verbesserter Wirkung
US20090196915A1 (en) * 2007-08-21 2009-08-06 Gary Van Nest Composition and methods of making and using influenza proteins
JP2010536907A (ja) * 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease
CN101820908A (zh) 2007-10-09 2010-09-01 科利制药公司 包含改性糖部分的免疫刺激寡核苷酸类似物
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
US7720322B2 (en) * 2008-06-30 2010-05-18 Intuitive Surgical, Inc. Fiber optic shape sensor
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US8053422B2 (en) * 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides

Also Published As

Publication number Publication date
AU5242498A (en) 1998-05-22
US20050070491A1 (en) 2005-03-31
CN100338086C (zh) 2007-09-19
WO1998018810A1 (en) 1998-05-07
US20050239732A1 (en) 2005-10-27
AU2004218696B2 (en) 2008-11-06
ES2268736T3 (es) 2007-03-16
US7888327B2 (en) 2011-02-15
CN1235609A (zh) 1999-11-17
US20050215500A1 (en) 2005-09-29
US20060003955A1 (en) 2006-01-05
US20060089326A1 (en) 2006-04-27
JP2003286174A (ja) 2003-10-07
US7723022B2 (en) 2010-05-25
US20050148537A1 (en) 2005-07-07
US8158592B2 (en) 2012-04-17
JP2010150280A (ja) 2010-07-08
US20070066553A1 (en) 2007-03-22
CN101265285A (zh) 2008-09-17
EP2322615A1 (de) 2011-05-18
ATE332966T1 (de) 2006-08-15
EP1714969A3 (de) 2010-03-03
US7723500B2 (en) 2010-05-25
US7517861B2 (en) 2009-04-14
US20030050261A1 (en) 2003-03-13
US20050267064A1 (en) 2005-12-01
US6207646B1 (en) 2001-03-27
DK0948510T3 (da) 2006-10-30
US20050032736A1 (en) 2005-02-10
JP5082063B2 (ja) 2012-11-28
DE69736331T2 (de) 2007-08-09
KR20000052994A (ko) 2000-08-25
NZ335397A (en) 2000-11-24
US20040198688A1 (en) 2004-10-07
JP2001503267A (ja) 2001-03-13
EP0948510A1 (de) 1999-10-13
JP2008289495A (ja) 2008-12-04
US8129351B2 (en) 2012-03-06
US20080031936A1 (en) 2008-02-07
US20050277604A1 (en) 2005-12-15
US20050277609A1 (en) 2005-12-15
CA2270345C (en) 2014-05-13
US20100125101A1 (en) 2010-05-20
US20040229835A1 (en) 2004-11-18
US20040167089A1 (en) 2004-08-26
US7879810B2 (en) 2011-02-01
CA2270345A1 (en) 1998-05-07
EP0948510A4 (de) 2000-08-02
KR100689942B1 (ko) 2007-03-09
US7402572B2 (en) 2008-07-22
US20070078104A1 (en) 2007-04-05
EP1746159A2 (de) 2007-01-24
US7674777B2 (en) 2010-03-09
US20050171047A1 (en) 2005-08-04
US20050049215A1 (en) 2005-03-03
ES2624859T3 (es) 2017-07-17
US20050049216A1 (en) 2005-03-03
US20050004061A1 (en) 2005-01-06
JP2004041224A (ja) 2004-02-12
US20050233999A1 (en) 2005-10-20
US20050233995A1 (en) 2005-10-20
AU2004218696A1 (en) 2004-11-04
PT948510E (pt) 2006-12-29
EP2360252B1 (de) 2017-02-08
EP1746159A3 (de) 2009-11-25
US20050054602A1 (en) 2005-03-10
US8258106B2 (en) 2012-09-04
EP2360252A1 (de) 2011-08-24
US20050123523A1 (en) 2005-06-09
EP1714969A2 (de) 2006-10-25
EP0948510B1 (de) 2006-07-12
US20090202575A1 (en) 2009-08-13
US8058249B2 (en) 2011-11-15
AU9724901A (en) 2002-02-07
US20040147468A1 (en) 2004-07-29
US20050059625A1 (en) 2005-03-17
EP2360252B8 (de) 2017-04-12
US20040132685A1 (en) 2004-07-08
AU775185B2 (en) 2004-07-22
US20080026011A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
EP0948510A4 (de) Immunstimulierende nukleinsaeuremolekuele
DE69535036D1 (de) Immunomodulatorische oligonukleotide
BG106538A (en) Immunostimulatory nucleic acids
BR9814483A (pt) "vacina"
EP1985702A3 (de) CPG-ähnliche Nukleinsäuren und Verwendungsverfahren dafür
ATE190981T1 (de) 2'-modifizierte nukleotide
IL139813A0 (en) Methods and products for inducing mucosal immunity
DK1296713T3 (da) Immunstimulerende oligodeoxynukleotider
AU1534795A (en) Modified oligonucleotides
DE69822871D1 (en) Chemische synthese von 6-o-alkyl erythromycin a
ES2093688T3 (es) Deteccion especifica del mycobacterium tuberculosis.
AU2002242900A1 (en) Conjugated homo-and copolymers comprising substituted or unsubstituted heteroaryl group, its preparation and uses
EP1346026A4 (de) 5'-inosinsäure herstellender mikroorganismus und verfahren zur herstellung von 5'- inosinsäure unter verwendung desselben
DK0725821T3 (da) Nucleinsyremarkørstige til estimering af masse
IT1231284B (it) Apparecchiatura per il condizionamento dell'aria, a duplice possibilita' di funzionamento.
ATE160354T1 (de) Oligonukleotide mit anti-cytomegalovirus wirkung
BR0012680A (pt) Transferência intensificada de calor de fluxo cruzado
IT1320168B1 (it) Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide.
FR2680797B1 (de)
IT8907091V0 (it) Diffusore per generatori di un flusso d'aria, segnatamente per apparecchi asciugacapelli
IT212844Z2 (it) Separatore d'aria di linea per impianti di riscaldamento.

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: WEINER, GEORGE, IOWA CITY, IA 52246, US

Inventor name: STEINBERG, ALFRED D., POTOMAC, MD 20854, US

Inventor name: KLINMAN, DENNIS, POTOMAC, MD 20854, US

Inventor name: KLINE, N., JOEL, IOWA CITY, IA 52242, US

Inventor name: KRIEG, ARTHUR M., WELLESLEY, MASS., US

8363 Opposition against the patent
8331 Complete revocation